Longevity Goes Mainstream
Muratcan Koylan@muratcan
−2.6%
since Sep 30
The idea
I believe medicine is shifting from treating sickness to catching it early, as insurers start covering preventive testing and GLP-1 drugs pull more people into routine screening. This basket tilts heaviest into early detection and monitoring, where approvals and coverage decisions can move things quickly, while GLP-1 leaders and lab and imaging networks round out the picture. I'm keeping a 10% cash reserve to add on dips, since a concentrated bet like this can swing hard, and I'm holding across the space rather than picking one name to be right.
What it owns
- Blood tests and genetic screens that catch disease before symptoms appear are the fastest-growing part of the shift toward prevention. · GrailIts Galleri blood test is the purest play on multi-cancer screening adoption by insurers and Medicare., Guardant HealthIts blood tests detect cancer and guide treatment, and its liquid biopsy screening business grows as payers expand coverage., Tempus AIIts AI tools help doctors read diagnostic data and catch disease earlier, adding a software layer to early detection., NateraIt turns genetic testing from specialty labs into routine screening for cancer recurrence and prenatal health.25%
- High-volume lab networks and imaging systems must process millions more tests and scans as prevention becomes routine. · Quest DiagnosticsIt operates one of the two largest lab networks and is pushing consumer-ordered tests directly to individuals., IlluminaIt makes the sequencing machines that run nearly every genetic test in the prevention ecosystem., LabcorpIt operates the other major lab network that processes the blood panels becoming a normal consumer habit., GE HealthCareIt makes the imaging scanners that early-detection programs rely on to screen for heart disease and other conditions.22%
- Wearable sensors that track health daily rather than annually are turning prevention into an ordinary consumer habit. · Abbott LaboratoriesIts Libre glucose monitor is the volume leader in wearable health tracking and also operates a major diagnostics network., DexcomIts continuous glucose monitors are moving from diabetics to health-conscious consumers, expanding the mainstream market., iRhythm TechnologiesIts wearable patches detect heart rhythm problems before they cause strokes, prevention at its most literal.17%
- Drugs that treat obesity and related conditions are pulling millions of people into preventive medicine as a mainstream habit. · Eli LillyIts GLP-1 drugs are the largest force pulling millions into preventive care and set the pace for the entire shift., Novo NordiskIt pioneered the GLP-1 wave and remains a core player in the obesity and prevention drug market., AmgenIt is developing a next-generation obesity drug as a challenger to the two dominant players in the prevention market.17%
- Direct-to-consumer health services and value-based primary care practices compete to sell prevention before sickness arrives. · Hims & Hers HealthIt delivers prevention directly to consumers through an app, selling weight loss drugs, labs and checkups out of pocket., Privia HealthIt operates primary care practices paid to keep patients healthy, aligning incentives with prevention rather than treating illness.9%
- Cash10%